Holen Sie sich die Stockscreener-App
94.35
1.80%
1.67
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$92.68
Offen:
$93.255
24-Stunden-Volumen:
3.02M
Relative Volume:
0.31
Marktkapitalisierung:
$120.67B
Einnahmen:
$407.94B
Nettoeinkommen (Verlust:
$2.90B
KGV:
41.43
EPS:
2.2771
Netto-Cashflow:
$7.39B
1W Leistung:
+7.77%
1M Leistung:
+6.20%
6M Leistung:
+23.20%
1J Leistung:
+14.39%
1-Tages-Spanne:
$93.20
$94.74
1-Wochen-Bereich:
$88.10
$93.34
52-Wochen-Spanne:
$69.51
$110.68
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, ELV, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
94.35 | 120.67B | 407.94B | 2.90B | 7.39B | 2.2771 |
UNH
Unitedhealth Group Inc
|
421.31 | 378.16B | 450.13B | 14.91B | 23.62B | 15.55 |
ELV
Elevance Health Inc
|
438.85 | 95.17B | 201.11B | 4.95B | 6.29B | 22.50 |
CI
Cigna Group
|
305.49 | 80.72B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
428.82 | 51.49B | 137.20B | 1.15B | 1.27B | 9.3439 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
Better Dividend Stock for Retirees: Bristol Myers Squibb vs. CVS Health - Yahoo Finance
CVS Health Corporation $CVS Holdings Cut by Jackson Square Capital LLC - MarketBeat
CVS Agrees To Pay $315 Million Over Unlawful Controlled Substance Prescriptions – Here's What Patients Should Know - Blavity News
CVS Health stock: Leerink cuts target for CVS Health stock from USD 119.00 to USD 112.00 - ad-hoc-news.de
Management Raised The Bar For CVS Health Stock; Does The Chart Agree? - Yahoo Finance
CVS Caremark: Why Transparency Matters in Pharmacy Benefits - Yahoo Finance
CVS Health Corporation $CVS Stock: SteelPeak Wealth LLC Raises Stake - MarketBeat
CVS Health (NYSE:CVS) Cut to Buy at Wall Street Zen - MarketBeat
CVS Health Corporation $CVS Position Cut by TD Waterhouse Canada Inc. - MarketBeat
CVS Pharmacy to pay $315 million over alleged illegal opioid dispensing, federal officials say - WV News
Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3? - Zacks Investment Research
How to prepare your household for cold and flu season - CVS Health
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research
39,202 CVS Health Corporation $CVS Shares Acquired by Triasima Portfolio Management inc. - MarketBeat
CVS Health Corporation $CVS Stock: Community Trust & Investment Co. Cuts Holdings - MarketBeat
CVS Health Corporation $CVS Stock Sold by Curated Wealth Partners LLC - MarketBeat
CVS Health Corporation $CVS Stock Acquired by Assenagon Asset Management S.A. - MarketBeat
CVS Health (CVS) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
CVS Health Corporation $CVS Holdings Increased by State of Alaska Department of Revenue - MarketBeat
Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? - Zacks Investment Research
CVS Health collaborates with The Midlife Collective to redefine a woman’s midlife health journey - CVS Health
RBC keeps USD 113.00 target for CVS Health stock at 25.01 percent upside - ad-hoc-news.de
75 million U.S. women are in the years around menopause. CVS will study midlife health. - Stock Titan
CVS HealthEarly Detection Matters: Finding Heart Health Risks Earlier - Yahoo Finance
CVS Health Corporation $CVS Shares Sold by Fort Washington Investment Advisors Inc. OH - MarketBeat
52,621 Shares in CVS Health Corporation $CVS Purchased by Western Financial Corp CA - MarketBeat
CVS Health Corp (CVS) Shares Surge 3.2% -- What GF Score of 79 T - GuruFocus
How CVS Health dispenses opioids responsibly - CVS Health
MinuteClinic earns Joint Commission accreditation for primary care - CVS Health
MinuteClinic earns 7th Joint Commission accreditation | CVS Stock News - Stock Titan
CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? - Zacks Investment Research
CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? - TradingView
CVS to pay $315M after settlement in DOJ lawsuit over controlled prescriptions - Yahoo Finance
UPDATED: CVS Agrees to Pay $315M for Illegally Filling Unlawful… - Go Local Prov
CVS Health Corporation $CVS Stock: NorthCrest Asset Manangement LLC Boosts Stake - MarketBeat
CVS Caremark is transforming the health care experience - CVS Health
CVS Health Corporation: Revenue and Earnings Analysts Forecasts Revisions | CVS | US1266501006 - marketscreener.com
CVS Health’s Valuation Suggests Opportunity, but Can Earnings Deliver? - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Douglas Lane & Associates LLC Reduces Holdings in CVS Health Corporation $CVS - MarketBeat
Beyond Halloween night: New ways to celebrate the season - CVS Health
CVS Health (CVS) vs Cigna (CI): Which is a Better Stock to Buy? - Yahoo Finance
Humana surges after topping 2027 Medicare star ratings - Reuters
CVS Stock: TD Cowen Warns Of Bottom-Line Pressure For CVS Health Amid Star Ratings Setback - Yahoo Finance
CVS Health Corporation $CVS Shares Purchased by Artemis Investment Management LLP - MarketBeat
Aetna 2027 Star ratings reflect strong clinical quality and member experience - CVS Health
233,794 CVS Health Corporation $CVS Shares Acquired by Hamlin Capital Management LLC - MarketBeat
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Zacks Investment Research
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Yahoo Finance Australia
CVS Caremark: Why transparency matters in pharmacy benefits - CVS Health
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvs Health Corp-Aktie (CVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROBBINS LARRY | Director |
May 21 '26 |
Sale |
93.45 |
370,462 |
34,619,007 |
4,824,799 |
| FARAH ROGER N | Director |
May 21 '26 |
Proposed Sale |
93.68 |
2,817 |
263,886 |
0 |
| ROBBINS LARRY | Director |
May 20 '26 |
Sale |
93.82 |
1,018,000 |
95,510,822 |
5,195,261 |
| ROBBINS LARRY | Director |
May 19 '26 |
Sale |
94.45 |
1,983,538 |
187,341,308 |
6,213,261 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer |
May 08 '26 |
Sale |
89.58 |
69,551 |
6,230,379 |
10,133 |
| TILAK MANDADI | Officer |
May 08 '26 |
Proposed Sale |
89.58 |
69,551 |
6,230,719 |
0 |
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):